Compare Citius Pharmaceuticals Inc (CTXR) vs Standard Lithium Ltd (SLI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Citius Pharmaceuticals Inc vs Standard Lithium Ltd — how do they compare? Citius Pharmaceuticals Inc trades at $0.53 (market cap $14.64M), while Standard Lithium Ltd trades at $2.31 (market cap $577.14M). The key difference: Standard Lithium Ltd is far larger — about 39.4× Citius Pharmaceuticals Inc's market cap. Which is the better fit depends on your goals.
| CTXR | SLI | |
|---|---|---|
Market Cap | $14.64M | $577.14M |
Sector | Health | Basic Materials |
52-Week High | $1.82 | $5.65 |
52-Week Low | $0.53 | $2.29 |
Enterprise Value | $10.86M | $436.34M |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CTXR trades at $0.54, down 7.33% in the last session, with a bearish technical signal from moving averages. The company reported a net loss of $37.43M for 2025 and has missed earnings expectations for the last three quarters. Recent news highlights progress with LYMPHIR, including Phase 1 data presentations at ASCO and international expansion, alongside $5.6M in net revenue for the first half of 2026.
Despite a high analyst buy consensus (83%), CTXR faces significant fundamental challenges with negative profitability and cash burn. Investment opportunity hinges on successful commercialization of LYMPHIR, but risks include ongoing losses, dilution from recent financing, and clinical execution uncertainties. The stock remains speculative with high risk-reward dynamics.
SLI trades at $2.29, down 6.91% today, with a bearish technical trend but oversold RSI readings. The company reported a net loss of $48.40 million in 2025, though it secured a $225 million DOE grant and key construction contracts for its Arkansas lithium project. Analyst consensus is unanimously bullish with 3 buy ratings.
The investment case hinges on successful project execution and lithium market dynamics. Near-term risks include cash burn and execution delays, but long-term upside exists if production targets are met. Investors should weigh high operational losses against strong institutional backing and strategic partnerships.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Citius Pharmaceuticals Inc
Citius Pharmaceuticals is a late-stage biopharmaceutical company focused on critical care products. Its pipeline includes anti-infectives and targeted immune therapies for conditions like cutaneous T-cell lymphoma.
Read more on CTXR →About Standard Lithium Ltd
Standard Lithium Ltd. is a company focused on the development of lithium projects in North America, with a primary focus on extracting lithium from brine resources. Their flagship projects aim to utilize proprietary, advanced direct lithium extraction (DLE) technologies to produce high-purity lithium compounds in an environmentally responsible manner. The company seeks to become a key domestic supplier to the growing electric vehicle and battery storage markets.
Read more on SLI →
